⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20462211 | 0.84 | ALDH1A1 (0.40) | — | |
| SCHEMBL10197447 | 0.81 | — | — | |
| SCHEMBL442394 | 0.79 | ALDH1A1 (0.42) | — | |
| SCHEMBL6225829 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL8973659 | 0.78 | — | — | |
| SCHEMBL21766160 | 0.78 | — | — | |
| SCHEMBL4445808 | 0.78 | — | — | |
| SCHEMBL20683887 | 0.77 | — | — | |
| SCHEMBL4578897 | 0.76 | CHRM2 (0.45) | — | |
| SCHEMBL8084905 | 0.76 | CHRM2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325699-A1 | POLYPEPTIDES AND METHODS OF USE | ALDEVRON LLC (US) | 2025-10-23 | — | — | US | claimed |
| US-20250235559-A1 | GENE EDITING REPORTER SYSTEM AND GUIDE RNA AND COMPOSITION RELATED THERETO; COMPOSITION AND METHOD FOR KNOCKING OUT DNA WITH MORE THAN TWO GRNAS; GENE EDITING IN THE EYE; AND GENE EDITING USING BASE EDITORS | Incisive Genetics Inc. (CA) | 2025-07-24 | — | — | US | claimed |
| EP-4409004-A1 | COMPOSITIONS AND METHODS FOR PREVENTING, AMELIORATING, OR TREATING SICKLE CELL DISEASE | The University of British Columbia (CA) | 2024-08-07 | — | — | EP | claimed |
| US-20240175012-A1 | GUIDE RNAS AND COMPOSITIONS FOR EDITING HUNTINGTIN GENE, AND METHODS RELATED THERETO | UNIV BRITISH COLUMBIA (CA) | 2024-05-30 | — | — | US | claimed |
| WO-2023079465-A1 | COMPOSITIONS AND METHODS FOR PREVENTING, AMELIORATING, OR TREATING SICKLE CELL DISEASE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-05-11 | — | — | WO | claimed |
| EP-4734964-A1 | LIPID PARTICLES FOR DELIVERING A PAYLOAD | Repertoire Immune Medicines, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260115138-A1 | LIPID NANOPARTICLES | CODEBRIDGEBIO INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260102345-A1 | POLYOXYALKYLENE-1,2-DIMYRISTOYL-GLYCEROL COMPOUNDS, WHEREIN THE POLYOXYALKYLENE IS A POLY(ETHYLENE OXIDE) HAVING C1 TO C3-ALKYLOXYMETHYL SIDE CHAINS | EVONIK OPERATIONS GMBH (DE) | 2026-04-16 | — | — | US | disclosed |
| US-20260055387-A1 | EFFECTOR PROTEINS, COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF | MAMMOTH BIOSCIENCES INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4689092-A1 | ENGINEERED EFFECTOR PROTEINS, COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF | Mammoth Biosciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4684779-A1 | LIPID NANOSYSTEMS | Diversa Technologies S.L. (ES) | 2026-01-28 | — | — | EP | disclosed |
| US-20260008887-A1 | LIPIDS CONJUGATED WITH POLY(ETHYLENE OXIDE) HAVING C1 TO C3-ALKYLOXYMETHYL SIDE CHAINS | EVONIK OPERATIONS GMBH (DE) | 2026-01-08 | — | — | US | disclosed |
| WO-2023081927-A2 | TREATING CHEMORESISTANT FORMS OF LEUKEMIA AND OTHER CANCERS THAT OVEREXPRESS RNA BINDING PROTEIN FXR1 | THE GENERAL HOSPITAL CORPORATION (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023079465-A1 | COMPOSITIONS AND METHODS FOR PREVENTING, AMELIORATING, OR TREATING SICKLE CELL DISEASE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-05-11 | — | — | WO | disclosed |
| US-7569676-B2 | Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1498415-B1 | Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs | ROCHE DIAGNOSTICS GMBH (DE) | 2007-06-27 | — | — | EP | disclosed |
| US-7060847-B2 | Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20050153439-A1 | Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs | GHOSHAL MITALI (US) | 2005-07-14 | — | — | US | disclosed |
| US-20050014210-A1 | Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs | ROCHE DIAGNOSTICS CORPORATION | 2005-01-20 | — | — | US | disclosed |
| EP-1498415-A1 | Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs | Roche Diagnostics GmbH (DE) | 2005-01-19 | — | — | EP | disclosed |